Table 4 The inter-relationship between clinico-pathological characteristics and blood vessel invasion (BVI FVIII ) in patients with primary operable invasive ductal breast cancer
All patients (n = 360) | BVIFVIII-ve | BVIFVIII+ ve | ( P-value) |
|---|---|---|---|
n = 301(84%) | n = 59(16%) |  | |
Age (≤50/ >50 years) | 104/197 | 21/38 | 0.848 |
Size (≤20/ 21-50/ >50 mm) | 168/123/10 | 17/39/3 | <0.001 |
Grade (I / II / III) | 45/104/152 | 3/20/36 | 0.044 |
Involved lymph node (-ve/+ve) | 185/116 | 21/38 | <0.001 |
ER status (no/yes) | 139/162 | 32/27 | 0.258 |
PR status (no/yes) | 158/143 | 36/23 | 0.230 |
HER2 status (no/yes) | 250/51 | 39/20 | 0.003 |
Endocrine therapy (no/yes) | 226/70 | 46/11 | 0.475 |
Chemotherapy (no/yes) | 178/118 | 31/26 | 0.419 |
Tumour recurrence (no/local/distant/both) | 243/13/42/3 | 28/4/25/2 | <0.001 |
Alive/cancer death/non cancer death | 179/60/62 | 10/37/12 | <0.001 |
Cancer specific survival (months)a | 181(173–189) | 93(73–112) | <0.001 |
Node-negative disease (n = 212) | n = 185 (90%) | n = 21 (10%) |  |
Age (≤50/ >50 years) | 58/132 | 10/12 | 0.157 |
Size (≤20/ 21-50/ >50 mm) | 118/69/3 | 6/15/1 | 0.002 |
Grade (I / II / III) | 36/66/88 | 1/9/12 | 0.180 |
ER status (no/yes) | 50/66 | 22/16 | 0.114 |
PR status (no/yes) | 58/58 | 23/15 | 0.261 |
HER2 status (no/yes) | 158/32 | 16/6 | 0.228 |
Endocrine therapy (no/yes) | 133/50 | 16/5 | 0.732 |
Chemotherapy (no/yes) | 129/54 | 13/8 | 0.419 |
Tumour recurrence (no/local/distant/both) | 163/9/15/3 | 12/0/10/0 | <0.001 |
Alive/cancer death/non cancer death | 125/24/41 | 3/11/8 | 0.001 |
Cancer specific survival (months)a | 194(186–202) | 110(75–146) | <0.001 |
Triple-negative patients (n = 120) | n = 104(87%) | n = 16(13%) |  |
Age (≤50/ >50 years) | 44/60 | 6/10 | 0.718 |
Size (≤20/ 21-50/ >50 mm) | 59/40/5 | 4/11/1 | 0.037 |
Grade (I / II / III) | 1/16/87 | 0/5/11 | 0.212 |
Involved lymph node (-ve/+ve) | 65/39 | 5/11 | 0.019 |
Endocrine therapy (no/yes) | 92/12 | 15/0 | 0.167 |
Chemotherapy (no/yes) | 45/59 | 6/9 | 0.812 |
Tumour recurrence (no/local/distant) | 81/3/20 | 7/0/9 | 0.002 |
Alive/cancer death/non cancer death | 64/24/16 | 2/13/1 | 0.014 |
Cancer specific survival (months)a | 172(157–186) | 64(37–92) | <0.001 |